Table 2 |
|
|
Apolar metabolites significantly affected by TCDD (p < 0.01) and average fold change ratio between treatments (TCDD vs. DMSO). |
|
|
GC-MS |
Ratio TCDD/DMSO (RTD) |
|
|
|
|
C12:0 |
0.78 |
|
C14:0 |
0.72 |
|
C14:1a |
0.70 |
|
C14:1b |
0.29 |
|
C16:1 (n-6) |
0.63 |
|
C16:1 (n-9) |
0.62 |
|
C17:0 |
1.20 |
|
C18:0 |
1.27 |
|
C18:1 (n-9) |
0.78 |
|
C18:1c |
0.72 |
|
C18:2a |
0.71 |
|
C18:2b |
0.63 |
|
C18:2c |
1.29 |
|
C18:2d |
0.64 |
|
C18:2e |
0.63 |
|
C20:1b |
0.79 |
|
C20:2a |
0.74 |
|
C20:2b |
0.70 |
|
C20:3a |
0.80 |
|
C20:3b |
0.64 |
|
C22:2 |
0.61 |
|
C22:3a |
0.73 |
|
|
|
|
1H NMR |
Ratio TCDD/DMSO (RTD) |
|
|
|
|
Total triglycerides |
0.51 |
|
Total cholesterol ester |
0.69 |
|
|
|
|
*Underscore letters indicate isomers (unidentified). Individual passage number results are in Additional File 1 (Tables S3 and S4). |
|
|
Ruiz-Aracama et al. BMC Genomics 2011 12:251 doi:10.1186/1471-2164-12-251 |
|
